FDA Approves Blood Test for Colorectal Cancer Screening

New Shield test aims to increase screening rates and early detection among average-risk adults aged 45 and older.

Shield detects DNA fragments from cancer cells in the blood, offering a less invasive screening option.
The test is 83% effective in identifying colorectal cancer but less effective for precancerous polyps.
FDA approval may lead to Medicare and private insurance coverage, making the test more accessible.
Patients testing positive with Shield will still need a follow-up colonoscopy for confirmation.
Colorectal cancer is the second-leading cause of cancer deaths in the US; increased screening could save many lives.